logo
Plus   Neg
Share
Email

Abbott Selects AbbVie As New Name For Future Research-Based Pharma Co.

Abbott (ABT) announced that AbbVie will be the name of the new, independent research-based pharmaceutical company it expects to launch by the end of 2012.

AbbVie, the research-based pharmaceutical company, will include Abbott's current portfolio of leading proprietary pharmaceuticals and biologics. The diversified medical products company, which will retain the Abbott name, will consist of Abbott's existing diversified medical products portfolio, including its branded generic pharmaceutical, devices, diagnostics and nutritional businesses.

Further, Richard Gonzalez, currently executive vice president, Global Pharmaceuticals, will become chairman and CEO of AbbVie. However, Miles White will remain chairman and CEO of Abbott.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Reigniting concerns about a global trade war, President Donald Trump announced plans to impose new tariffs on billions of dollars worth of Chinese imports on Friday. Trump said in a statement the U.S. will implement a 25 percent tariff on $50 billion of goods from China that contain "industrially significant technologies." Investors may want to take note of shares of school bus maker Blue Bird Corp. (BLBD) that are 17% off their 52-week high of $24.99, and at an attractive price point. Significant growth potential in Alternative-Fuel offerings, product differentiation & upgrades, compelling industry attributes, growing profitability, rising interest in Electric Buses, and strong Free cash flow generation make this s A full-time minimum wage worker cannot afford a two-bedroom rental apartment anywhere in the U.S. despite the increase in state and city minimum wages, according to report from the National Low Income Housing Coalition or NLIHC. The NLIHC's "Out of Reach" 2018 annual report calculates the gap between wages and the costs of rental housing across the U.S.
Follow RTT